Literature DB >> 20569489

Digital gangrene associated with anticentromere antibodies: a case report.

Lauren Bolster1, Regina M Taylor-Gjevre, Bindu Nair, John A Gjevre.   

Abstract

INTRODUCTION: Anticentromere antibodies have been associated with peripheral vascular occlusive disease, most frequently accompanied by sclerodactyly in the context of a connective tissue disorder. We report a case of digital gangrene with no other clinical associations except positive anticentromere antibodies. CASE
PRESENTATION: Our patient, a 53-year-old Caucasian woman, non-smoker, presented with progressive pain and blackening of the distal right third finger over the preceding five weeks. No sclerodactyly was evident. She was anticentromere antibody positive at greater than 100 U/mL. Angiography revealed diffuse distal vasculopathy in both upper extremities. Other investigations were unremarkable.
CONCLUSIONS: It is rare for anticentromere antibody-associated digital necrosis to develop without concomitant sclerodactyly. However, this patient's case illustrates the need to consider an autoimmune contribution to the pathogenesis of digital ischemia even in the absence of a recognizable connective tissue disease.

Entities:  

Year:  2010        PMID: 20569489      PMCID: PMC2901265          DOI: 10.1186/1752-1947-4-189

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  22 in total

1.  Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis.

Authors:  F M Wigley; R A Wise; R Miller; B W Needleman; R J Spence
Journal:  Arthritis Rheum       Date:  1992-06

2.  Six cases positive for anti-centromere antibodies with ulcer and gangrene in the extremities.

Authors:  M Takahashi; J Okada; H Kondo
Journal:  Br J Rheumatol       Date:  1997-08

Review 3.  Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases.

Authors:  P M Seferović; A D Ristić; R Maksimović; D S Simeunović; G G Ristić; G Radovanović; D Seferović; B Maisch; M Matucci-Cerinic
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

4.  Raynaud's phenomenon, anticentromere antibodies, and digital necrosis without sclerodactyly: an entity independent of scleroderma?

Authors:  E M Sachsenberg-Studer; C Prins; J H Saurat; D Salomon
Journal:  J Am Acad Dermatol       Date:  2000-10       Impact factor: 11.527

5.  Antibodies to membranes of endothelial cells and fibroblasts in scleroderma.

Authors:  M B Hill; J L Phipps; R J Cartwright; A Milford Ward; M Greaves; P Hughes
Journal:  Clin Exp Immunol       Date:  1996-12       Impact factor: 4.330

6.  Clinical and serological heterogeneity in patients with anticentromere antibodies.

Authors:  Shoji Miyawaki; Hiroko Asanuma; Susumu Nishiyama; Yasuhiko Yoshinaga
Journal:  J Rheumatol       Date:  2005-08       Impact factor: 4.666

7.  Patients with anticentromere antibodies, clinical features, diagnoses and evolution.

Authors:  P G Vlachoyiannopoulos; A A Drosos; A Wiik; H M Moutsopoulos
Journal:  Br J Rheumatol       Date:  1993-04

8.  Systemic sclerosis and digital gangrene without scleroderma.

Authors:  W G Barr; J A Robinson
Journal:  J Rheumatol       Date:  1988       Impact factor: 4.666

Review 9.  Vascular complications of scleroderma.

Authors:  Serena Guiducci; Roberto Giacomelli; Marco Matucci Cerinic
Journal:  Autoimmun Rev       Date:  2007-01-12       Impact factor: 9.754

10.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

View more
  2 in total

1.  Prevalence and predictive factors of osteoporosis in systemic sclerosis patients: a case-control study.

Authors:  Mathilde Marot; Antoine Valéry; Eric Esteve; Guido Bens; Adelheid Müller; Stéphanie Rist; Hechmi Toumi; Eric Lespessailles
Journal:  Oncotarget       Date:  2015-06-20

2.  Digital gangrene associated with anticentromere antibodies.

Authors:  Mary Grace; Es Dhanesh
Journal:  Indian J Dermatol       Date:  2014-03       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.